Status:
TERMINATED
Longitudinal Assessment of Arthralgia and Related Symptoms in Breast Cancer Patients Receiving Aromatase Inhibitors
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborating Sponsors:
AstraZeneca
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
The goal of this research study is to learn more about what it is like for patients with breast cancer to receive treatment with the drug anastrozole. Researchers want to learn about possible symptoms...
Detailed Description
Study Groups: If you agree to take part in this study, you will be assigned to one of two groups, depending on how long you have been receiving anastrozole treatment. If you are within two months pri...
Eligibility Criteria
Inclusion
- Patients with early stage hormone receptor positive breast cancer who are at these 2 time points in their anastrozole treatment: 1) at the time period between two months prior or one month after beginning of their anastrozole treatment (Cohort 1); 2) patients within +/- 2 months of the beginning of the third year of anastrozole treatment (Cohort 2).
- Patients \>= 18 years old.
Exclusion
- Patients with metastatic disease.
- Patients who cannot complete the assessment tools.
- Patients without telephone access.
Key Trial Info
Start Date :
June 5 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 28 2019
Estimated Enrollment :
102 Patients enrolled
Trial Details
Trial ID
NCT00738998
Start Date
June 5 2008
End Date
June 28 2019
Last Update
January 2 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030